NASDAQ:XFOR - X4 Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $18.00
Forecasted Upside: 122.22 %
Number of Analysts: 4
Breakdown:
0 Sell Ratings
0 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$8.10 As of 05/10/2021 04:04 PM ET

▲ +0.05 (0.62%)

1 month | 3 months | 12 months

Get New X4 Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for XFOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XFOR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$18.00

▲ +122.22% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for X4 Pharmaceuticals in the last 3 months. The average price target is $18.00, with a high forecast of $21.00 and a low forecast of $15.00. The average price target represents a 122.22% upside from the last price of $8.10.

Buy

The current consensus among 4 contributing investment analysts is to buy stock in X4 Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/16/2019

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/14/2020

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/14/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/12/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/10/2020

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/8/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/9/2021

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/9/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/22/2021	Oppenheimer	Reiterated Rating	Buy	$16.00	High	i
12/17/2020	Brookline Capital Management	Initiated Coverage	Buy	$21.00	High	i Rating by L. Cann at Brookline Capital Management
11/30/2020	B. Riley	Reiterated Rating	Buy	$15.00	Medium	i Rating by Mayank Mamtani at B. Riley
11/9/2020	Canaccord Genuity	Lower Price Target	Buy	$22.00 ➝ $20.00	High	i
6/12/2020	B. Riley	Reiterated Rating	Buy	$15.00	Medium	i Rating by Mayank Mamtani at B. Riley
5/26/2020	Canaccord Genuity	Reiterated Rating	Buy		High	i
5/8/2020	B. Riley	Lower Price Target	Buy	$19.00 ➝ $15.00	Medium	i Rating by Mayank Mamtani at B. Riley
5/8/2020	HC Wainwright	Lower Price Target	Outperform	$22.00 ➝ $21.00	Medium	i Rating by S. Ramakanth at HC Wainwright
5/7/2020	Oppenheimer	Reiterated Rating	Buy	$20.00	Medium	i Rating by Leland Gershell at Oppenheimer Holdings Inc.
4/12/2020	HC Wainwright	Reiterated Rating	Buy	$22.00	High	i Rating by S. Ramakanth at HC Wainwright
3/26/2020	Citigroup	Lower Price Target	Buy	$16.00 ➝ $15.00	High	i Rating by Joel Beatty at Citigroup Inc.
3/13/2020	B. Riley	Lower Price Target	Buy	$25.00 ➝ $19.00	Medium	i Rating by Mayank Mamtani at B. Riley
3/12/2020	Cowen	Reiterated Rating	Buy		Medium	i Rating by Marc Frahm at Cowen Inc
2/13/2020	Roth Capital	Reiterated Rating	Buy		Medium	i Rating by Zegbeh Jallah at Roth Capital
1/7/2020	HC Wainwright	Initiated Coverage	Buy	$22.00	Low	i Rating by S. Ramakanth at HC Wainwright
12/23/2019	Oppenheimer	Initiated Coverage	Outperform	$20.00	High	i
12/18/2019	Roth Capital	Initiated Coverage	Buy	$20.00	Medium	i
12/9/2019	Citigroup	Upgrade	Neutral ➝ Buy	$16.00 ➝ $20.00	Medium	i
12/5/2019	B. Riley	Initiated Coverage	Buy	$25.00	High	i
10/10/2019	Cowen	Reiterated Rating	Buy		Low	i Rating by Marc Frahm at Cowen Inc
9/30/2019	Cowen	Reiterated Rating	Buy		Low	i Rating by Marc Frahm at Cowen Inc
6/7/2019	Stifel Nicolaus	Initiated Coverage	Buy ➝ Buy	$27.00	High	i
6/5/2019	Cowen	Initiated Coverage	Outperform ➝ Outperform		Low	i
5/21/2019	Canaccord Genuity	Initiated Coverage	Buy	$27.00	Medium	i

(Data available from 5/10/2016 forward)

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and WaldenstrÃ¶m macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $8.10

$7.92

$8.14

50 Day Range

MA: $8.93

$8.00

$10.28

52 Week Range

Now: $8.10

$5.38

$11.11

Volume

1,819 shs

Average Volume

106,507 shs

Market Capitalization

$140.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of X4 Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on X4 Pharmaceuticals in the last twelve months: B. Riley, Brookline Capital Management, Canaccord Genuity, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for XFOR.

What is the current price target for X4 Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for X4 Pharmaceuticals in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 122.2%. Brookline Capital Management has the highest price target set, predicting XFOR will reach $21.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $15.00 for X4 Pharmaceuticals in the next year.
View the latest price targets for XFOR.

What is the current consensus analyst rating for X4 Pharmaceuticals?

X4 Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XFOR will outperform the market and that investors should add to their positions of X4 Pharmaceuticals.
View the latest ratings for XFOR.

What other companies compete with X4 Pharmaceuticals?

Other companies that are similar to X4 Pharmaceuticals include Poseida Therapeutics, Solid Biosciences, Compugen, Precision BioSciences, Oyster Point Pharma, Gritstone Oncology, Lineage Cell Therapeutics, Aptose Biosciences, Jounce Therapeutics, Codiak BioSciences, Outlook Therapeutics, Fusion Pharmaceuticals, Adverum Biotechnologies, AVROBIO and Opthea.

How do I contact X4 Pharmaceuticals' investor relations team?

X4 Pharmaceuticals' physical mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company's listed phone number is 857-529-8300 and its investor relations email address is [email protected] The official website for X4 Pharmaceuticals is www.x4pharma.com.